Dantari, a Thousand Oaks, CA-based clinical-stage biotechnology firm, raised $47M in Collection A funding.
The spherical was led by Westlake Village BioPartners with participation from Nook Ventures, Alexandria Enterprise Investments, and Caltech. The corporate additionally introduced the appointment of Richard A. Markus, M.D., Ph.D., as president and chief govt officer (CEO), and its board of administrators, chaired by Sean Harper, M.D., a co-founding managing director at Westlake.
The corporate intends to make use of the funds for the development of its differentiated antibody-drug conjugate (ADC) and chemotherapeutic platforms.
Led by CEO Richard A. Markus, Dantari is a clinical-stage biotechnology firm growing focused therapeutics for the remedy of cancers and different illnesses. The corporate is advancing a pipeline of T-HDC (Focused Excessive-capacity Drug Conjugate) chemotherapeutic brokers beginning with DAN-222 and next-generation ADC therapeutics T-HDC expertise originating from Caltech. Dantari’s HDC and T-HDC platform expertise makes use of chemically outlined polymers with a excessive drug-antibody ratio (DAR), and a excessive diploma of management and adaptability to optimize efficiency of focused drug conjugates that may leverage validated targets throughout a broad vary of therapeutic payload choices.
FinSMEs
08/12/2022
